Glucose-lowering effect of BTS 67 582

British Journal of Pharmacology
T Page, C J Bailey

Abstract

1. The hypoglycaemic effect of BTS 67 582 (1,1-dimethyl-2(2-morpholinophenyl) guanidine fumarate) was studied in normal rats. 2. BTS 67 582 (100 mg kg(-1), p.o.) acutely lowered basal plasma glucose concentrations: onset within 1 h, maximum decrease of >40% at 2-3 h, and partial return to euglycaemia by 5 h. Plasma insulin concentrations were increased: onset within 30 min, maximum increase 3 fold at 1-2 h; returning to normal by 5 h. 3. BTS 67 582 (100 mg kg(-1)) increased (by 56%) the rate of disappearance of plasma glucose during an intravenous glucose tolerance test, accompanied by a 51% increase in insulin concentrations. 4. During hyperglycaemic clamp studies BTS 67 582 (100 mg kg(-1)) increased glucose utilization 3 fold. This was associated with a 3 fold increase in insulin concentrations, even in the presence of adrenaline at a dosage which inhibits glucose-induced insulin release. 5. When the insulin-releasing effect of BTS 67 582 (100 mg kg(-1)) was inhibited by infusion of somatostatin, there was no effect on glycaemia. 6. Insulin-dependent diabetic BB/S rats, which do not produce endogenous insulin, showed no effect of BTS 67 582 (100 mg kg(-1)) on plasma glucose concentrations in the presence or absence of exogeno...Continue Reading

References

Sep 1, 1978·The Journal of Clinical Investigation·A D CherringtonJ L Chiasson
Dec 15, 1992·Biochimica Et Biophysica Acta·S J Ashcroft, F M Ashcroft
Dec 1, 1992·General and Comparative Endocrinology·G F Jacobs, E R Kühn
Apr 1, 1992·British Journal of Pharmacology·C J BaileyC Day
Jun 1, 1992·Diabetes Care·L C Groop
Jun 1, 1992·Diabetes Care·C J Bailey
Aug 1, 1990·Diabetes Care·W J Malaisse, P Lebrun
Apr 1, 1971·Clinica Chimica Acta; International Journal of Clinical Chemistry·J F Stevens
Nov 1, 1971·The Journal of Clinical Endocrinology and Metabolism·B Desbuquois, G D Aurbach
Jul 12, 1995·Annals of the New York Academy of Sciences·N G MorganE Tsoli
Nov 1, 1994·British Journal of Clinical Pharmacology·W D ByromJ R Bratty
Nov 1, 1993·General Pharmacology·C J Bailey
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Mar 1, 1997·British Journal of Pharmacology·R B JonesW R Buckett

❮ Previous
Next ❯

Citations

Jul 6, 2000·Trends in Endocrinology and Metabolism : TEM·R Perfetti, A Ahmad
May 12, 2000·British Journal of Pharmacology·N H McClenaghanP R Flatt
Mar 3, 1999·The Journal of Pharmacy and Pharmacology·D A Storey, C J Bailey
Jul 5, 2005·Expert Opinion on Investigational Drugs·N G Morgan
Aug 13, 1999·Drug and Chemical Toxicology·J St Papadopulos, C A Liapi
Nov 28, 2006·Phytotherapy Research : PTR·L GrantA M Warnock
Jul 3, 2002·Biochemical Pharmacology·Ingo Rustenbeck
Apr 13, 2000·Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism·M Nattrass, C J Bailey
Nov 11, 2005·The Journal of Pharmacology and Experimental Therapeutics·Joy K SahaJoseph A Jakubowski
Jan 2, 2001·Endocrine Reviews·S MatthaeiH U Häring

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.